Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Safety evaluation of a recombinant plasmin derivative lacking kringles 2-5 and rt-PA in a rat model of transient ischemic stroke.

Crumrine RC, Marder VJ, Taylor GM, LaManna JC, Tsipis CP, Novokhatny V, Scuderi P, Petteway SR Jr, Arora V.

Exp Transl Stroke Med. 2012 May 16;4(1):10. doi: 10.1186/2040-7378-4-10.

2.

Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model.

Crumrine RC, Marder VJ, Taylor GM, Lamanna JC, Tsipis CP, Scuderi P, Petteway SR Jr, Arora V.

Exp Transl Stroke Med. 2011 Sep 20;3(1):10. doi: 10.1186/2040-7378-3-10.

3.

Haemostatic safety of a unique recombinant plasmin molecule lacking kringles 2-5.

Marder VJ, Manyak S, Gruber T, Goyal A, Moreno G, Hunt J, Bromirski J, Scuderi P, Petteway SR Jr, Novokhatny V.

Thromb Haemost. 2010 Oct;104(4):780-7. doi: 10.1160/TH09-10-0742. Epub 2010 Aug 30.

PMID:
20806125
4.

Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin.

Hunt JA, Petteway SR Jr, Scuderi P, Novokhatny V.

Thromb Haemost. 2008 Sep;100(3):413-9.

PMID:
18766256
5.

Critical factors influencing prion inactivation by sodium hydroxide.

Bauman PA, Lawrence LA, Biesert L, Dichtelmüller H, Fabbrizzi F, Gajardo R, Gröner A, Jorquera JI, Kempf C, Kreil TR, von Hoegen I, Pifat DY, Petteway SR Jr, Cai K.

Vox Sang. 2006 Jul;91(1):34-40.

PMID:
16756599
6.

Comment: comparisons of Aralast and Prolastin, alpha1-protease inhibitors for treatment of alpha1-antitrypsin deficiency.

Petteway SR Jr.

Ann Pharmacother. 2006 Feb;40(2):353-4; author reply 354. Epub 2006 Jan 31. No abstract available.

PMID:
16449545
7.

Clearance of prions during plasma protein manufacture.

Burdick MD, Pifat DY, Petteway SR Jr, Cai K.

Transfus Med Rev. 2006 Jan;20(1):57-62.

PMID:
16373188
8.

Ensuring the biologic safety of plasma-derived therapeutic proteins: detection, inactivation, and removal of pathogens.

Cai K, Gierman TM, Hotta J, Stenland CJ, Lee DC, Pifat DY, Petteway SR Jr.

BioDrugs. 2005;19(2):79-96. Review.

PMID:
15807628
9.

An improved Western blot assay to assess the clearance of prion protein from plasma-derived therapeutic proteins.

Hartwell RC, Nelson MS, Kislan MM, Stenland CJ, Miller JL, Pifat DY, Petteway SR Jr, Cai K.

J Virol Methods. 2005 May;125(2):187-93.

PMID:
15794989
10.

Immunoglobulin replacement therapy in primary antibody deficiency diseases--maximizing success.

Durandy A, Wahn V, Petteway S, Gelfand EW.

Int Arch Allergy Immunol. 2005 Mar;136(3):217-29. Epub 2005 Feb 15. Review.

PMID:
15713984
11.

Evaluation of virus and prion reduction in a new intravenous immunoglobulin manufacturing process.

Trejo SR, Hotta JA, Lebing W, Stenland C, Storms RE, Lee DC, Li H, Petteway S, Remington KM.

Vox Sang. 2003 Apr;84(3):176-87.

PMID:
12670366
12.

Partitioning of human and sheep forms of the pathogenic prion protein during the purification of therapeutic proteins from human plasma.

Stenland CJ, Lee DC, Brown P, Petteway SR Jr, Rubenstein R.

Transfusion. 2002 Nov;42(11):1497-500.

PMID:
12421224
13.

Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.

Korneyeva M, Hotta J, Lebing W, Rosenthal RS, Franks L, Petteway SR Jr.

Biologicals. 2002 Jun;30(2):153-62.

PMID:
12127317
14.

Solvent-dependent precipitation of prion protein.

Cai K, Miller JL, Stenland CJ, Gilligan KJ, Hartwell RC, Terry JC, Evans-Storms RB, Rubenstein R, Petteway SR Jr, Lee DC.

Biochim Biophys Acta. 2002 May 20;1597(1):28-35.

PMID:
12009399
15.

Pathogen safety of manufacturing processes for biological products: special emphasis on KOGENATE Bayer.

Lee DC, Miller JL, Petteway SR Jr.

Haemophilia. 2002 Mar;8 Suppl 2:6-9. Review.

PMID:
11966845
16.

Ensuring the pathogen safety of intravenous immunoglobulin and other human plasma-derived therapeutic proteins.

Miller JL, Petteway SR Jr, Lee DC.

J Allergy Clin Immunol. 2001 Oct;108(4 Suppl):S91-4. Review.

PMID:
11586272
17.

A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteins.

Lee DC, Stenland CJ, Miller JL, Cai K, Ford EK, Gilligan KJ, Hartwell RC, Terry JC, Rubenstein R, Fournel M, Petteway SR Jr.

Transfusion. 2001 Apr;41(4):449-55. Erratum in: Transfusion 2001 Aug;41(8):1079.

PMID:
11316893
18.

Monitoring plasma processing steps with a sensitive Western blot assay for the detection of the prion protein.

Lee DC, Stenland CJ, Hartwell RC, Ford EK, Cai K, Miller JL, Gilligan KJ, Rubenstein R, Fournel M, Petteway SR Jr.

J Virol Methods. 2000 Jan;84(1):77-89.

PMID:
10644089
19.

HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.

Lawless MK, Barney S, Guthrie KI, Bucy TB, Petteway SR Jr, Merutka G.

Biochemistry. 1996 Oct 22;35(42):13697-708.

PMID:
8885850
20.

Structure-activity relationships of novel hematoregulatory peptides.

Bhatnagar PK, Agner EK, Alberts D, Arbo BE, Callahan JF, Cuthbertson AS, Engelsen SJ, Fjerdingstad H, Hartmann M, Heerding D, Hiebl J, Huffman WF, Hysben M, King AG, Kremminger P, Kwon C, LoCastro S, Løvhaug D, Pelus LM, Petteway S, Takata JS.

J Med Chem. 1996 Sep 13;39(19):3814-9.

PMID:
8809169
21.

Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates.

Dukes CS, Matthews TJ, Lambert DM, Dreyer GB, Petteway SR, Weinberg JB.

AIDS Res Hum Retroviruses. 1996 Jun 10;12(9):777-82.

PMID:
8738429
22.

Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion.

Lambert DM, Barney S, Lambert AL, Guthrie K, Medinas R, Davis DE, Bucy T, Erickson J, Merutka G, Petteway SR Jr.

Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2186-91.

23.

Effects of SKF 108922, an HIV-1 protease inhibitor, on retrovirus replication in mice.

Black Pl, Ussery MA, Barney S, Wittrock R, DeMarsh P, Dreyer GB, Petteway SR Jr, DalMonte P, Baldoni J, Lambert D.

Antiviral Res. 1996 Mar;29(2-3):175-86.

PMID:
8739597
25.

Efficacy of the hematoregulatory peptide SK&F 107647 in experimental systemic Candida albicans infections in normal and immunosuppressed mice.

DeMarsh PL, Sucoloski SK, Frey CL, Bhatnagar PK, Koltin Y, Actor P, Petteway SR.

Immunopharmacology. 1994 May-Jun;27(3):199-206.

PMID:
7520890
26.

In vivo modulation of hematopoiesis by a novel hematoregulatory peptide.

Pelus LM, King AG, Broxmeyer HE, DeMarsh PL, Petteway SR, Bhatnagar PK.

Exp Hematol. 1994 Mar;22(3):239-47.

PMID:
8112423
27.

Synergistic drug interactions of an HIV-1 protease inhibitor with AZT in different in vitro models of HIV-1 infection.

Lambert DM, Bartus H, Fernandez AV, Bratby-Anders C, Leary JJ, Dreyer GB, Metcalf BW, Petteway SR Jr.

Antiviral Res. 1993 Aug;21(4):327-42.

PMID:
7692816
28.

Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in tissue culture.

Black PL, Downs MB, Lewis MG, Ussery MA, Dreyer GB, Petteway SR Jr, Lambert DM.

Antimicrob Agents Chemother. 1993 Jan;37(1):71-7.

29.
30.

Human immunodeficiency virus type 1 protease inhibitors irreversibly block infectivity of purified virions from chronically infected cells.

Lambert DM, Petteway SR Jr, McDanal CE, Hart TK, Leary JJ, Dreyer GB, Meek TD, Bugelski PJ, Bolognesi DP, Metcalf BW, et al.

Antimicrob Agents Chemother. 1992 May;36(5):982-8.

31.

V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity.

Ivanoff LA, Dubay JW, Morris JF, Roberts SJ, Gutshall L, Sternberg EJ, Hunter E, Matthews TJ, Petteway SR Jr.

Virology. 1992 Apr;187(2):423-32.

PMID:
1546447
32.

Human chromosome-dependent and -independent pathways for HIV-2 trans-activation.

Hart CE, Westhafer MA, Galphin JC, Ou CY, Bacheler LT, Petteway SR Jr, Wasmuth JJ, Chen IS, Schochetman G.

AIDS Res Hum Retroviruses. 1991 Nov;7(11):877-82.

PMID:
1760228
33.

Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain.

Ivanoff LA, Looney DJ, McDanal C, Morris JF, Wong-Staal F, Langlois AJ, Petteway SR Jr, Matthews TJ.

AIDS Res Hum Retroviruses. 1991 Jul;7(7):595-603.

PMID:
1768461
34.

Binding of soluble CD4 proteins to human immunodeficiency virus type 1 and infected cells induces release of envelope glycoprotein gp120.

Hart TK, Kirsh R, Ellens H, Sweet RW, Lambert DM, Petteway SR Jr, Leary J, Bugelski PJ.

Proc Natl Acad Sci U S A. 1991 Mar 15;88(6):2189-93.

35.

The chronically infected cell as a target for the treatment of HIV infection and AIDS.

Petteway SR Jr, Lambert DM, Metcalf BW.

Trends Pharmacol Sci. 1991 Jan;12(1):28-34. Review.

PMID:
1672479
36.

Morphometric analysis of recombinant soluble CD4-mediated release of the envelope glycoprotein gp120 from HIV-1.

Kirsh R, Hart TK, Ellens H, Miller J, Petteway SA Jr, Lambert DM, Leary J, Bugelski PJ.

AIDS Res Hum Retroviruses. 1990 Oct;6(10):1209-12. No abstract available.

PMID:
2252640
37.

Human chromosome 12 is required for elevated HIV-1 expression in human-hamster hybrid cells.

Hart CE, Ou CY, Galphin JC, Moore J, Bacheler LT, Wasmuth JJ, Petteway SR Jr, Schochetman G.

Science. 1989 Oct 27;246(4929):488-91.

PMID:
2683071
38.

Monoclonal antibodies to HTLV-III451 gp41: delineation of an immunoreactive conserved epitope in the transmembrane region of divergent isolates of HIV-1.

Veronese FD, Rahman R, Kalyanaraman VS, Pal R, Lusso P, Tritch R, Petteway S, Gallo RC, Sarngadharan MG.

AIDS Res Hum Retroviruses. 1989 Oct;5(5):479-86.

PMID:
2480151
39.

Stable indicator cell lines exhibiting HIV-1 tat function.

Bacheler LT, Strehl LL, Neubauer RH, Petteway SR Jr, Ferguson BQ.

AIDS Res Hum Retroviruses. 1989 Jun;5(3):275-8.

PMID:
2543431
40.

Chemical synthesis and expression of a gene encoding HIV-1 TAT protein.

Ferguson BQ, Friedland BK, Hendrickson E, Strehl L, Petteway SR, Jonak GJ.

Biochem Biophys Res Commun. 1989 May 15;160(3):1429-37.

PMID:
2543400
41.

Antibodies from human immunodeficiency virus-infected individuals bind to a short amino acid sequence that elicits neutralizing antibodies in animals.

Kenealy WR, Matthews TJ, Ganfield MC, Langlois AJ, Waselefsky DM, Petteway SR Jr.

AIDS Res Hum Retroviruses. 1989 Apr;5(2):173-82.

PMID:
2469449
42.

HIV-1-specific production of IFN-gamma and modulation by recombinant IL-2 during early HIV-1 infection.

Rinaldo C, Piazza P, Wang YZ, Armstrong J, Gupta P, Ho M, Petteway S, Reed D, Lyter D, Kingsley L.

J Immunol. 1988 May 15;140(10):3389-93.

PMID:
2452186
43.

Antibodies reactive with human immunodeficiency virus gag-coded antigens (gag reactive only) are a major cause of enzyme-linked immunosorbent assay reactivity in a blood donor population.

Tribe DE, Reed DL, Lindell P, Kenealy WR, Ferguson BQ, Cybulski R, Winslow D, Waselefsky DM, Petteway SR Jr.

J Clin Microbiol. 1988 Apr;26(4):641-7.

44.

Formation of poliovirus RNA polymerase 3D in Escherichia coli by cleavage of fusion proteins expressed from cloned viral cDNA.

Richards OC, Ivanoff LA, Bienkowska-Szewczyk K, Butt B, Petteway SR Jr, Rothstein MA, Ehrenfeld E.

Virology. 1987 Dec;161(2):348-56.

PMID:
2825408
45.

The sor gene of HIV-1 is required for efficient virus transmission in vitro.

Fisher AG, Ensoli B, Ivanoff L, Chamberlain M, Petteway S, Ratner L, Gallo RC, Wong-Staal F.

Science. 1987 Aug 21;237(4817):888-93.

PMID:
3497453
46.

Analysis of human serum antibodies to human immunodeficiency virus (HIV) using recombinant ENV and GAG antigens.

Kenealy W, Reed D, Cybulski R, Tribe D, Taylor P, Stevens C, Matthews T, Petteway S.

AIDS Res Hum Retroviruses. 1987 Spring;3(1):95-105.

PMID:
3304356
47.

Anti-GP 120 antibodies from HIV seropositive individuals mediate broadly reactive anti-HIV ADCC.

Lyerly HK, Reed DL, Matthews TJ, Langlois AJ, Ahearne PA, Petteway SR Jr, Weinhold KJ.

AIDS Res Hum Retroviruses. 1987;3(4):409-22.

PMID:
2833917
48.

HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope.

Putney SD, Matthews TJ, Robey WG, Lynn DL, Robert-Guroff M, Mueller WT, Langlois AJ, Ghrayeb J, Petteway SR Jr, Weinhold KJ, et al.

Science. 1986 Dec 12;234(4782):1392-5.

PMID:
2431482
49.

Expression and site-specific mutagenesis of the poliovirus 3C protease in Escherichia coli.

Ivanoff LA, Towatari T, Ray J, Korant BD, Petteway SR Jr.

Proc Natl Acad Sci U S A. 1986 Aug;83(15):5392-6.

50.

Viral therapy: prospects for protease inhibitors.

Korant BD, Towatari T, Ivanoff L, Petteway S Jr, Brzin J, Lenarcic B, Turk V.

J Cell Biochem. 1986;32(2):91-5.

PMID:
3023407

Supplemental Content

Loading ...
Support Center